Antidiabetics Archives

FDA approves Farxiga for treating heart failure risk

Antidiabetics, Approvals, Blockbusters, Blood Sugar, Cardiovascular Risk, FDA, FDA/Regulatory, Heart Attacks, Heart Failure, Kidney Failure, New Indications, SGLT2 Inhibitors, Strokes, Type 2 Diabetes

AstraZeneca’s blockbuster drug Farxiga won U.S. approval as a treatment to reduce the chances of hospitalization for heart failure in adults with type 2 diabetes and other cardiovascular risks.

FDA fast tracks AstraZeneca’s diabetes drug Farxiga

Antidiabetics, Blockbusters, Chronic Kidney Disease, Diabetes, Fast Track Designation, FDA, FDA/Regulatory, Heart Failure, Kidney Failure, SGLT2 Inhibitors

The U.S. Food and Drug Administration granted fast track status for the development of AstraZeneca’s diabetes drug Farxiga to prevent heart and kidney failure in patients with chronic kidney disease.

Certain Patients with Type 2 Diabetes Less Likely to Suffer Heart Failure While Taking New Class of Antidiabetic Drug

Antidiabetics, Clinical Trials, DPP-IV Inhibitors, Heart Failure, Hospitalizations, Seniors, SGLT2 Inhibitors, Studies, Type 2 Diabetes

Seniors with type 2 diabetes or those with diabetic complications were less likely to be hospitalized for heart failure while taking a sodium-glucose co-transporter 2 (SGLT2) inhibitor compared to dipeptidyl peptidase-4 (DPP4) inhibitors, another new class of oral antidiabetic drug, according to a study released in Cardiovascular Diabetology and conducted by Anthem Inc. and HealthCore.